Suppr超能文献

心房颤动抗凝治疗患者中与高血压相关的中风和出血风险:一项随机对照试验的荟萃分析

Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials.

作者信息

Harskamp Ralf E, Lucassen Wim A M, Lopes Renato D, Himmelreich Jelle C L, Parati Gianfranco, Weert Henk C P M van

机构信息

Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Academic Medical Center, AZ Amsterdam, The Netherlands.

Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.

出版信息

Acta Cardiol. 2022 May;77(3):191-195. doi: 10.1080/00015385.2021.1882111. Epub 2021 Mar 8.

Abstract

BACKGROUND AND PURPOSE

Hypertension is common in patients with atrial fibrillation (AF) and carries an additional risk for complications, most notably stroke and bleeding. We assessed the history of hypertension, level of blood pressure control, and an interaction with the choice of oral anticoagulants on clinical outcomes.

METHODS

We performed a systematic review and meta-analysis of studies that randomised patients to novel oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) and reported outcomes stratified by presence of hypertension. Collected outcomes were: ischaemic stroke or systemic embolism (SE), haemorrhagic stroke, intracranial haemorrhage and major bleeding. Log adjusted hazard ratios (HR) and corresponding standard error were calculated, and HRs were compared using Mantel-Haenszel random effects. Quality of the evidence was assessed with Cochrane risk of bias tool.

RESULTS

Five high-quality studies were eligible, including 71.527 participants who received NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) or VKAs, with median follow-up of 1.8-2.8 years. Compared with patients without hypertension, those with hypertension had higher adjusted risk for ischaemic stroke/SE (HR: 1.25, 95%-CI:1.09, 1.43) and haemorrhagic stroke (HR:1.98, 1.24-3.16). On a continuous scale, the risk of ischaemic stroke/SE increased 6-7% per 10 mmHg increase in systolic blood pressure. No interactions were found between the efficacy or safety of NOACs versus VKAs in the presence or absence of hypertension. In both groups, the use of NOACs led to a lower risk of ischaemic stroke/SE, haemorrhagic stroke and intracranial haemorrhage compared with patients that used VKAs.

CONCLUSIONS

Adequate blood pressure management is vital to optimally reduce the risk of stroke in patients with atrial fibrillation. The benefits of NOACs over VKAs, also apply to patients with elevated blood pressure.

摘要

背景与目的

高血压在心房颤动(AF)患者中很常见,并且会增加并发症风险,最显著的是中风和出血。我们评估了高血压病史、血压控制水平以及口服抗凝剂的选择与临床结局之间的相互作用。

方法

我们对将患者随机分为新型口服抗凝剂(NOACs)或维生素K拮抗剂(VKAs)并按高血压的存在情况分层报告结局的研究进行了系统评价和荟萃分析。收集的结局包括:缺血性中风或全身性栓塞(SE)、出血性中风、颅内出血和大出血。计算对数调整风险比(HR)和相应的标准误差,并使用Mantel-Haenszel随机效应比较HR。证据质量使用Cochrane偏倚风险工具进行评估。

结果

五项高质量研究符合条件,包括71527名接受NOACs(阿哌沙班、达比加群、依度沙班、利伐沙班)或VKAs的参与者,中位随访时间为1.8至2.8年。与无高血压患者相比,高血压患者发生缺血性中风/SE(HR:1.25,95%CI:1.09,1.43)和出血性中风(HR:1.98,1.24 - 3.16)的调整风险更高。在连续尺度上,收缩压每升高10 mmHg,缺血性中风/SE的风险增加6 - 7%。在有或无高血压的情况下,未发现NOACs与VKAs在疗效或安全性方面存在相互作用。在两组中,与使用VKAs的患者相比,使用NOACs导致缺血性中风/SE、出血性中风和颅内出血的风险更低。

结论

充分的血压管理对于最佳降低心房颤动患者的中风风险至关重要。NOACs优于VKAs的益处也适用于血压升高的患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验